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ABSTRACT
Background: Cyclin-Dependent Kinases (CDKs) are established anti-cancer drug 
targets and a new generation of CDK inhibitors are providing clinical benefits to 
a sub-set of breast cancer patients. We have recently shown that human CDK18 
promotes efficient cellular responses to replication stress. In the current study, 
we have investigated the clinicopathological and functional significance of CDK18 
expression levels in breast cancers.
Results: High CDK18 protein expression was associated with a triple negative and 
basal-like phenotype (p = 0.021 and 0.027 respectively) as well as improved patient 
survival, which was particularly significant in ER negative breast cancers (n = 594, Log 
Rank 6.724, p = 0.01) and those treated with chemotherapy (n = 270, Log Rank 4.575, 
p = 0.03). In agreement with these clinical findings, breast cancer cells genetically 
manipulated using a dCRISPR approach to express high levels of endogenous CDK18 
exhibited an increased sensitivity to replication stress-inducing chemotherapeutic 
agents, as a consequence to defective replication stress signalling at the molecular level.
Conclusions: These data reveal that CDK18 protein levels may predict breast 
cancer disease progression and response to chemotherapy, and provide further 
rationale for potential targeting of CDK18 as part of novel anti-cancer strategies for 
human cancers.
Materials and Methods: CDK18 protein expression was evaluated in 1650 breast 
cancers and correlated to clinicopathological parameters and survival outcomes. 
Similar analyses were carried out for genetic and transcriptomic changes in 
CDK18 within several publically available breast cancer cohorts. Additionally, we 
used a deactivated CRISPR/Cas9 approach (dCRISPR) to elucidate the molecular 
consequences of heightened endogenous CDK18 expression within breast cancer cells. 
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INTRODUCTION
Breast cancer is the most prevalent cancer in 
women worldwide, and the second most common cancer 
overall behind lung cancer. In the UK, around 50,000 
new breast cancer cases are diagnosed each year, and 
breast cancer accounts for around 12,000 deaths each 
year [1]. Many breast cancers do not respond well to 
traditional chemotherapy, and triple-negative tumours are 
particularly difficult to successfully treat. As such, new 
approaches and agents are currently being sought for the 
treatment for these tumours [1, 2]. Cyclin dependent 
kinases (CDKs) are an evolutionary conserved family of 
over 20 distinct Ser/Thr kinases that regulate both normal 
cycle progression and various stress-induced cell cycle 
checkpoints [3]. The importance of CDKs in controlling 
cellular growth/proliferation is highlighted by the high 
prevalence of dysfunction and/or aberrant expression 
of this family of proteins within human cancers [4]. As 
such, the development of small molecule CDK inhibitors 
(CDKi) has been the focus of many research groups and 
the pharmaceutical industry over the past 20 years [5]. 
Unfortunately, specific and selective targeting of individual 
CDKs has proved difficult, giving rise to non-specific 
activity and detrimental toxicities, which has hindered 
wide-scale use of CDKi within the clinic. However, recent 
advancements in the development of the next generation 
of specific CDKi combined with the emergence of more 
reliable and informative biomarkers have reinvigorated 
the field of CDKi [5]. This is especially true for breast 
cancer, where the CDK4/6 inhibitors Palbociclib/Ibrance 
(Pfizer), Ribociclib/Kisqali (Novartis & Astex) and 
Abemaciclib/Verzenio (Eli Lilly) were recently licensed 
for use in combination with hormonal-based therapies 
for the management of ER+/HER2-advanced metastatic 
breast cancers due to the significant progression-free 
survival benefits it offers these patients [68]. These recent 
discoveries have led to an increased interest in targeting 
other CDKs within breast tumours [9].
We recently reported functional characterisation of 
the human CDK family member CDK18, demonstrating 
that it promotes robust activation of ATR-mediated 
signalling in response to replication stress [10]. Elevated 
replication stress is prevalent in a high proportion of 
human cancers, which is often driven by the activation 
of oncogenes [11, 12]. As such, targeting of factors that 
lead to catastrophic levels of replication stress within 
cancer cells is an active area of both pre-clinical and 
clinical research [1315]. Due to its cellular functions, 
CDK18 therefore represents a potential novel anti-
cancer drug target, both as a mono-therapeutic approach 
in cancers with high levels of replication stress, and as 
part of combination approaches with chemotherapeutic 
agents that induce high levels of replication stress and/or 
DNA damage. Here we report our analysis of differential 
CDK18 mRNA and protein expression levels in relation 
to clinicopathological parameters within human breast 
cancers utilising large independent breast cancer clinical 
cohorts. We also report our phenotypic characterisation of 
deactivated dCRISPR-mediated genetically engineered 
breast cancer cell models that over express the endogenous 
CDK18 gene, and how these phenotypes may relate to our 
findings in breast cancer patients. 
RESULTS
Genomic and transcriptomic analysis of CDK18 
in human breast cancers.
As part of our interest in a potential role for 
CDK18 in cancer biology and putative therapeutic 
target, we interrogated CDK18 genomic alterations in 
a range of published cancer genome databases. From 
162 studies representing over 45,000 samples, CDK18 
gene amplification (due to copy number variance gain) 
was vastly more prevalent than deletions or mutations, 
with 4 out of the top 5 incidences of reported CDK18 
amplification occurring in breast cancer cohorts 
(Figure 1A). Indeed, CDK18 amplification was prevalent 
in the majority of all the reported breast cancer cohorts 
(representing ~6000 samples), ranging from ~526%, with 
an average amplification of 11.3% (Figure 1B). Based on 
these findings, we next investigated whether alterations 
in CDK18 at the transcriptomic level within breast cancer 
cohorts might be associated with various aspects of tumour 
biology and/or patient prognosis. As the largest CDK18 
gene amplification occurs within METABRIC dataset 
(Figure 1A and 1B), which is the most comprehensive 
breast cancer cohort for which detailed clinicopathological 
information is known [16], we further interrogated CDK18 
mRNA expression levels within this cohort. Overall, there 
was no significant correlation between CDK18 mRNA 
expression levels and clinicopathological parameters 
(Supplementary Table 1). However, elevated CDK18 
mRNA expression (above median) was associated with 
reduced patient survival across the whole cohort (n = 
1975, Log Rank -5.139, p = 0.02), which was also true 
for ER- tumours (n = 437, Log Rank 3.729, p = 0.05), 
but not for ER+ tumours (Figure 1C). Strikingly, breast 
cancers exhibiting elevated CDK18 mRNA expression 
were associated with a poorer response to the commonly 
used replication stress-inducing chemotherapeutic agents 
5-FU, cyclophosphamide and methotrexate (n = 416, Log 
Rank -3.901, p = 0.04; Figure 1C). This is consistent with 
our recent findings demonstrating that CDK18 promotes 
robust cellular responses to chemically induced replication 
stress [10]. However, in contrast to these findings, analysis 
of combined EGA and TCGA breast cancer samples (KM 
Plotter) suggests that high (above median) rather than low 
levels of CDK18 mRNA expression are associated with 
better patient survival (n = 3951, Log Rank P = 4.1e8; 
Figure 1D), with a similar trend for ER- tumours (n = 801, 
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HR = 0.81, Log Rank P = 0.075; Figure 1E), but not ER+ 
tumours (n = 2061, HR = 1, Log Rank P = 0.98; data not 
shown). Although gene amplification often leads to a 
subsequent increased mRNA and/or protein expression, it 
is commonly accepted that this is not always the case [17]. 
This is in part due to the genomic loci of the amplification, 
the complex compound genetic changes that occur 
within tumours, and the numerous epigenetic regulatory 
mechanisms that can negate gene amplification at both the 
mRNA and protein level [17]. Overall, these data suggest 
that subsequent CDK18 protein expression levels and/
or cellular activity might be important for aspects breast 
cancer biology and treatment outcomes.
CDK18 protein expression in human breast 
cancers and clinicopathological associations.
The associations between CDK18 amplification 
and/or mRNA expression levels with breast cancer 
patient survival prompted us to investigate CDK18 
protein expression within breast cancers in relation to 
clinicopathological phenotypes. To facilitate quantitative 
immunohistochemical studies, FFPE sections of breast 
cancer cells transfected with either non-targeting control 
siRNA or previously validated CDK18 siRNA [10] were 
used to optimise IHC staining conditions (Supplementary 
Figure 1A and 1B). To validate the optimised CDK18 
antibody conditions on human tissue sections, CDK18 
immunohistochemical staining was assessed in commercial 
breast cancer tissue microarrays comprising of over 360 
core biopsies of various cancer lineages, stage and grade, 
as well as normal healthy breast tissue and cancer adjacent 
controls (Supplementary Figure 1C). Consistent with our 
localisation studies in mammalian cell lines [10], and that 
many DDR proteins reside and function within both the 
cytoplasm and nucleus, CDK18 was expressed in both the 
nucleus and cytoplasm of breast tissue (Supplementary 
Figure 1A1C). Interestingly, increased CDK18 expression 
was associated with cancerous tissue compared to healthy 
and non-cancerous adjacent tissue (OR = 9.655, p =< 0.001; 
Supplementary Figure 1C and 1D), although CDK18 
expression did not continue to increase beyond grade 2 
tumours within these tissue microarrays (Supplementary 
Figure 1D). However, these TMAs only contained 23 
grade 3 tumours compared with 63 grade 1 and 170 grade 
2 tumours.
Using these optimised IHC conditions, we proceeded 
to investigate CDK18 protein expression in the Nottingham 
Tenovus series of 1650 breast cancers for which detailed 
clinicopathological parameters and various molecular 
markers have been previously defined [1821]. Similar to 
the commercial breast cancer TMAs, we observed nuclear 
as well as cytoplasmic staining of CDK18, however, 
nuclear expression was rare and cytoplasmic expression 
was more common within these samples (Figure 2A). High 
cytoplasmic CDK18 protein expression was associated 
with triple negative and basal-like phenotype (p = 0.021 
and p = 0.027 respectively; Table 1), and low levels of 
CDK18 expression were strongly correlated with HER2 
overexpression (p < 0.001; Table 1). Furthermore, high 
cytoplasmic CDK18 expression was associated with 
markers of DNA repair (Table 2), including high ATR 
(p = 0.005), high APE1 (pKLJK3ROȕp < 0.001) 
and high DNA-PK
cs
 (p < 0.001). Similarly, high cytoplasmic 
CDK18 expression was also linked to markers of cell 
cycle regulation (Table 2), such as phosphorylated CHK1 
(pCHK1; p = 0.001), high p16 (p = 0.018), high CHK2 
(p = 0.002), high CDK1 (p = 0.004) and high MDM2 
(p = 0.047). In terms of survival outcomes, low CDK18 
protein expression was associated with poorer patient 
survival (n = 1200, Log Rank 3.631, p = 0.06; Figure 2B), 
which was particularly significant within the ER- cohort, 
where high cytoplasmic CDK18 was associated with an 
overall better survival (p = 0.010; Figure 2C), and in patients 
that received chemotherapy (p = 0.032; Figure 2D). In the 
sub-group that received CMF based chemotherapy, there 
was a similar trend with better survival in patients with high 
cytoplasmic CDK18 expressing tumours (p = 0.07; Figure 
2E), but not in patients who received anthracycline-based 
chemotherapy (Figure 2F). Consistent with CDK18 mRNA 
expression, CDK18 protein expression did not influence 
survival within ER+ tumours, (Supplementary Figure 2A
2C). Collectively, these data suggest that CDK18 expression 
could potentially predict response to chemotherapeutic 
agents, and may influence certain aspects of breast cancer 
biology.
Heightened expression of endogenous CDK18 in 
breast cancer cells leads to defective replication 
stress signalling
To further understand our findings in the clinical 
cohorts, we next investigated the consequences of increased 
CDK18 expression at a molecular level using breast 
cancer cell culture models. To achieve this, we employed 
a deactivated CRISPR/Cas9 system to up-regulate the 
endogenous CDK18 promoter in MDA-MB-231 breast 
cancer cells due to its phenotypic comparison with difficult to 
treat breast cancers e.g. triple negative status and intermediate 
response to chemotherapy [22]. We also attempted to 
generate similar CDK18 cell models in the normal breast 
epithelial cell line MCF-10A, but were unable to generate 
viable clones (data not shown). Using this approach, we 
generated 2 separate sub-clones that exhibited between 510 
fold increased expression of endogenous CDK18 mRNA 
over parental MDA-MB-231 cells (Figure 3A), resulting in 
an ~4-fold increase in endogenous CDK18 protein expression 
(Figures 3B, 4A and 4B). As we have recently shown that 
cells with depleted levels of CDK18 exhibit elevated 
levels of DNA damage due to defects in replication stress 
signalling [10], we assessed endogenous DNA damage levels 
in these CDK18 activation clones using the DNA damage 
Oncotarget29511www.oncotarget.com
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PDUNHUȖ+$;,QFRQWUDVWWR&'.GHSOHWHGFHOOV>@
ZHGLGQRWREVHUYHDQ\GLIIHUHQFHVLQQXFOHDUIRFLȖ+$;
between the activation clones and parental cells (Figure 3C), 
however, the activation clones exhibited a significant increase 
LQSDQQXFOHDUȖ+$;VWDLQLQJ)LJXUH&ZKLFKLVRIWHQ
associated with aberrant replication processes [10, 23]. 
Consistent with these findings, the CDK18 activation clones 
exhibited reduced phosphorylation of the replication stress 
marker RPA2 in response to chemically induced replication 
stress (Figure 3D). 
These data suggest that similar to what we have 
recently reported for CDK18-depleted cells [10]; heightened 
expression of endogenous CDK18 compromises ATR-
mediated replication stress signalling. Indeed, we found 
that ATR activation and subsequent phosphorylation of key 
downstream targets in response to replication stress was 
abrogated in both CDK18-activaiton clones compared with 
parental MDA-MB-231 cells (Figure 4A). Our previous 
studies have revealed that CDK18 physically interacts with 
RAD9 [10], a key component of the 9-1-1 replication stress 
signalling complex, and promotes its phosphorylation on 
proline-directed CDK sites that are critical for establishing 
an efficient cellular response to replication stress [2426]. 
Consistent with defective replication stress signalling, 
MDA-MB-231 cells exhibiting heightened levels of 
endogenous CDK18 also display reduced phosphorylation 
of RAD9 at putative CDK sites (Figure 4B), which again 
phenocopies that of CDK18-deificent cells [10]. This 
highlights a likely molecular mechanism to the underlying 
ATR signalling defect observed in these cells, particularly 
as significant differences in either cell growth or cell 
cycle were not observed in the CDK18 activation clones 
compared to parental cells (Supplementary Figure 2D and 
2E). Finally, we assessed the phenotypic consequences 
of the reduced replication stress signalling in the CDK18 
activation clones by carrying out clonogenic survival 
assays using the breast cancer chemotherapeutic agents 
5-FU and Methotrexate. As shown in Figure 4C, both 
CDK18 activation clones exhibited an increased sensitivity 
to these replication stress inducing agents compared with 
parental MDA-MB-231 cells (Figure 4C). Overall, the data 
from the CDK18 activation clones is consistent with our 
findings in breast cancer clinical cohorts, where elevated 
levels of endogenous CDK18 protein expression confers 
an improved repose to chemotherapeutic agents that induce 
high levels of replication stress.
DISCUSSION 
Our findings reveal that amplification of the CDK18 
gene locus and CNV gains are widespread across human 
cancers, with a particularly high prevalence in breast 
cancers. We also find that breast cancers exhibit higher 
levels of both CDK18 mRNA and protein compared with 
normal breast tissue. However, it is difficult to disseminate 
if these are beneficial alterations actively selected for 
during tumourigenesis, or merely a consequence of 
other genetic changes that have occurred through the 
development of these tumours. If alterations in CDK18 
expression are indeed beneficial to tumour development, 
our data suggest that this may be a complex relationship 
in breast cancer. For example, we observed opposite 
survival associations between heightened CDK18 mRNA 
and protein expression in two large breast cancer cohorts 
(>1600 patients each), although such discrepancies may 
in part due to the fact that mRNA and protein expression 
levels often do not correlate. Indeed, analysis of a sub-
population of 86 samples within the Nottingham Tenovus 
breast cancer cohort for which both CDK18 protein and 
mRNA expression levels were determined, revealed 
no correlation between CDK18 mRNA and protein 
expression levels (Supplementary Figure 2F). 
One possible way in which differential CDK18 
expression may arise in human tumours is as a result of 
elevated replication stress within the cancerous cells. It 
is well established that tumours often possess high levels 
of replication stress due to the activation of oncogenes 
that can drive genetic alterations through myriad different 
mechanisms [11, 12, 2730]. Cellular DNA damage 
response mechanisms have evolved to act as a barrier to the 
potential pro-mutagenic increase in DNA damage that can 
arise through heightened replication stress, and often exhibit 
differential expression/activity in human tumours [11, 27, 
28, 31, 32]. Additionally, previous work from several 
groups has suggested that specific thresholds of replication 
stress may exists within different tumour populations that 
could exert important biological consequences for tumour 
development and growth and impact on further mutations/
genetic alterations that facilitate tumour development [11, 
12, 14, 30, 33]. Intriguingly, a recent report identified CNV 
gains and increased CDK18 mRNA expression in several 
distinct tumour populations from within a diffuse intrinsic 
pontine glioma, suggesting a selection preference for such 
Figure 1: Genetic and transcriptomic analysis of CDK18 in breast cancer cohorts. (A) Prevalence of CDK18 amplification 
(red; mainly due to copy number variance gains), deletion (blue) and mutations (green) across human cancers (derived from cBioPortal; 
http://www.cbioportal.org/). Pink circles under the bar chart represent breast cancer cohorts, which show a high prevalence for CDK18 
amplification. (B) CDK18 amplification from the cBioPortal data stratified for breast cancer cohorts, showing high frequency of CDK18 
CNV gains across multiple breast cancer cohorts (pink circles). (C) KaplanMeier survival curves derived from analysis of the METABRIC 
dataset of around 1980 breast cancer patients, plotted for CDK18 mRNA expression against breast cancer-specific survival (BCSS) and 
stratified as indicated above each graph. The chemotherapy data was derived from patients whose tumours were treated with the replication 
stress-inducing agents 5-FU, methotrexate and/or cyclophosphamide. (D) KaplanMeier survival curves of CDK18 mRNA expression 
(above or below median mRNA expression levels across the cohorts) derived from combined TGCA and EGA breast cancer cohorts 
(KMplotter; [45]; http://kmplot.com/analysis/index.php?p=service). (E) Same as in (D), but stratified for ER- tumours.
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Figure 2: Analysis of CDK18 protein expression in the Nottingham Tenovus breast cancer cohort. (A) Examples of 
negative control staining (left panel) and a CDK18 positively stained core breast cancer TMA (right panel), with enlarged images below 
highlighting the high prevalence of cytoplasmic CDK18 expression. (B) KaplanMeier survival curves for CDK18 protein expression 
(above or below median) plotted against breast cancer specific survival in the whole Nottingham Tenovus breast cancer cohort. (CF) 
KaplanMeier survival curves for CDK18 protein expression (above or below median) plotted against breast cancer specific survival for 
the ER- tumours within the Nottingham Tenovus breast cancer cohort stratified using the indicated clinicopathological parameters. CMF; 
tumours treated with the combination cyclophosphamide, methotrexate and 5-FU clinical chemotherapeutic regime. 
Oncotarget29514www.oncotarget.com
genetic alterations to CDK18 expression during tumour 
development [34].
Given that CDK18 functions to facilitate robust 
replication stress signalling [10], any elevated levels of 
CDK18 in human cancers may simply be a consequence 
of heightened levels of replication stress and such 
increased levels of CDK18 could interfere with the finely 
controlled feedback regulation mechanisms controlling 
replication stress signalling, ultimately leading to a 
dominant-negative type disruption to CDK18s normal 
cellular functions. As such, CDK18 expression levels 
may provide more significant biological roles in different 
tumour populations depending on the underlying levels 
of replication stress and functional status of the various 
DNA damage response & cell cycle checkpoint machinery. 
Indeed, we found that CDK18 protein expression was 
significantly correlated with expression levels of DNA 
repair factors and cell cycle checkpoint regulators within 
human breast cancer samples. Specifically, we found that 
high levels of CDK18 protein expression were associated 
with high levels of phosphorylated CHK1, which is an 
established marker of increased replication stress [14]. 
Consistent with this finding, CDK18 protein levels were 
also associated with high ATR protein expression; the key 
kinase that acts upstream of CHK1 to regulate cellular 
responses to replication stress [35]. Furthermore, we found 
that high levels of CDK18 were also associated with high 
levels of TOPBP1 and DNA-PK
cs
, which represent both an 
established and newly realised factor in cellular responses 
to replication stress within human cells [36, 37]. It would 
Table 1: Association of CDK18 protein expression with aggressive tumour genotypes/phenotypes in the Nottingham 
Tenovus breast cancer cohort
Variable
CDK18 (cytoplasmic) Protein Expression
P- value
Low
N (%)
High
N (%)
Mitotic Index 
M1 (low; mitoses < 10)
M2 (medium; mitoses 1018)
M3 (high; mitosis > 18)
308 (33.8)
172 (18.9)
430 (47.3)
88 (30.1)
61 (20.9)
143 (49.0)
0.470
Her2 overexpression
No
Yes
775 (86.3)
123 (13.7)
272 (95.1)
14 (4.9)
5.0 × 105
Triple Negative Phenotype
No
Yes
737 (82.4)
157 (17.6)
219 (76.3)
68 (23.7)
0.021
Basal Like Phenotype
No
Yes
765 (88.9)
96 (11.1)
233 (83.8)
45 (16.2)
0.027
Cytokeratin 6 (CK6)
Negative
Positive
651 (84.2)
122 (15.8)
197 (82.1)
43 (17.9)
0.434
Cytokeratin 14 (CK14)
Negative
Positive
667 (86.7)
102 (13.3)
215 (90.0)
24 (10.0)
0.188
Cytokeratin 18 (CK18)
Negative
Positive
73 (10.1)
652 (89.9)
27 (12.4)
191 (87.6)
0.330
Cytokeratin 19 (CK19)
Negative
Positive
49 (6.4)
712 (93.6)
13 (5.4)
226 (94.6)
0.576
ATF2
Low
High
351 (50.8)
 340 (49.2)
110 (48.9)
115 (51.5)
0.619
HER2: human epidermal growth factor receptor 2; CK: cytokeratin; Basal-like: ER-, HER2 and positive expression of 
either CK5/6, CK14 or EGFR; Triple negative: ER-/PgR-/HER2-.
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Table 2: Association of CDK18 protein expression with protein expression of the indicated DNA repair factor, cell 
cycle or apoptotic regulator within the Nottingham Tenovus breast cancer cohort
Variable
CDK18 (cytoplasmic) Protein Expression 
P- valueLow
N (%)
High
N (%)
BRCA1          
Absent
Normal
135 (20.8)
513 (79.2)
34 (16.3)
175 (83.7)
0.149
XRCC1              
Low
High
117 (17.7)
543 (82.3)
27 (12.4)
191 (87.6)
0.065
FEN1         
Low
High
469 (74.9)
157 (25.1)
134 (69.1)
60 (30.9)
0.107
SMUG1         
Low
High
241 (39.6)
367 (60.4
69 (35.4)
126 (64.6)
0.288
APE1
Low
High
416 (54.6)
346 (45.4)
92 (36.7)
159 (63.3)
1.0 × 106
3ROȕ
Low
High
344 (43.2)
453 (56.8)
73 (27.2)
195 (72.8)
4.0 × 106
ATR 
Low
High
521 (68.8)
236 (31.2)
152 (59.1)
105 (40.9)
0.005
ATM 
Low
High
296 (52.9)
264 (47.1)
92 (51.4)
87 (48.6)
0.733
DNA-PKcs 
Low
High
285 (39.3)
441 (60.7)
56 (23.6)
181 (76.4)
1.3 × 105
P16
Low
High
544 (88.0)
74 (12.0)
167 (81.5)
38 (18.5)
0.018
P21
Low
High
369 (55.8)
292 (44.2)
113 (56.5)
87 (43.5)
0.866
MIB1           
Low
High
339 (45.9)
400 (54.1)
96 (39.3)
148 (60.7)
0.075
P53       
Low expression
High expression
595 (79.4)
154 (20.6)
176 (75.5)
57 (24.5)
0.205
Bcl-2              
Negative
Positive
309 (37.5)
515 (62.5)
84 (33.2)
169 (66.8)
0.214
TOP2A          
Low
Overexpression
310 (49.1)
322 (50.9)
82 (36.9)
140 (63.1)
0.002
pChk1 (Nuclear)           
Low
High
801 (87.5)
114 (12.5)
220 (74.3)
76 (25.7)
1.0 × 106
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therefore be interesting to further investigate potential 
relationships between endogenous levels of replication 
stress and CDK18 expression in other cancer cohorts. 
The most established cellular marker of replication stress 
is phosphorylated RPA2 (pRPA), but to our knowledge, 
pRPA levels have not been assessed in large cancer patient 
cohorts, although some initial IHC findings with pRPA2 
antibodies are starting to emerge [33], which may help 
facilitate such future studies. 
Within our study, we also find that the association 
between CDK18 mRNA or protein expression and patient 
survival is complex within the context of ER status. 
Our original findings in the METABRIC suggested 
that high mRNA levels of CDK18 were associated with 
poor survival, which was also true for in ER-, but not 
ER+ tumours. However, subsequent analysis of CDK18 
protein levels in the Nottingham Tenovus breast cancer 
cohort revealed better survival in ER- tumours that have 
higher than median levels of CDK18, which is also true in 
ER- MDA-MB-231 breast cancer cell lines overexpressing 
endogenous CDK18 when treated with chemotherapeutic 
agents. Functional links between the DNA damage 
response and hormone receptor signalling pathways 
have been previously reported [2, 38, 39], although the 
mechanisms by which these two pathways interact have 
not been fully elucidated [38]. Recent pre-clinical and 
clinical studies have demonstrated the advantage of 
inhibiting CDK4/6 driven proliferation in advanced ER+ 
tumours [6, 7]. Therefore, targeting of other CDKs in 
cancers with specific genetic backgrounds, phenotypic 
traits and/or ER status may yield equally promising 
results [3, 5, 9, 40]. Indeed, CDK18s role in facilitating 
efficient cellular responses to replication stress make it an 
attractive therapeutic target in many cancers, including in 
breast cancer where strong associations between oestrogen 
receptor signalling, cell proliferation and replication stress 
are emerging [2, 38, 39]. Our data therefore add to the 
growing interest in the role of CDKs within breast cancer 
biology and clinical management strategies, and suggest 
that further study of CDK18 within other cancers is 
warranted.
MATERIALS AND METHODS
Cell culture and generation of CRISPR/
deactivated Cas9 activation clones
MDA-MB-231 and MCF-7 breast cancer cells were 
maintained as adherent monolayer cultures in DMEM 
media containing 10% FBS at 37° C in a humidified 
atmosphere of 5% CO
2
. Stable CDK18 CRISPR/
deactivation Cass9 CDK18 activation clones were created 
using the standard Santa Cruz Biotechnology protocol. 
Briefly, 1 × 105 cells were seeded into 1 well of a 6 well 
plate. The following day, 1 ml of media was replaced with 
1 ml of fresh FCS free media supplemented with 5 ug/ml 
of polybrene (SCBT sc-134220) and 20 ul of CDK18 
lentiviral particles (SCBT SC-422147). The following 
day, growth media was replaced with fresh media 
supplemented with 10% FCS, 2 ug/ml Puromycin 
(SBCT sc-108071), 300 ug/ml Hygromycin (SBCT sc-
29067) and 2 ug/ml Blastacidin (SBCT sc-495389). On 
day 5, 100 cells were seeded into one 10 cm plate with 
continued selection. These were left for a further 10 days 
and individual clones picked, sub-cultured and analysed 
by RT-PCR and western blotting to confirm activation of 
the endogenous CDK18 gene promoter.
Immunofluorescence
1.2 × 103 cells were seeded onto 200 mm glass 
cover slips in 6 well plates and incubated for 24 hrs for 
the cells to adhere. Following appropriate siRNA and/or 
drug treatments, cells were fixed in either ice-cold 100% 
methanol or 4% PFA for 10 minutes (depending on the 
antibody used). Coverslips were washed briefly in PBS 
pChk1 (Cytoplasmic)           
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314 (34.3)
601 (65.7)
72 (24.3)
224 (75.7)
0.001
Chk2           
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139 (66.5)
5.0 × 10-6
Bax            
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157 (29.7)
111 (66.1)
57 (33.9)
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CDK1              
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414 (72.9)
154 (27.1)
114 (61.6)
71 (38.4)
0.004
MDM2             
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495 (78.0)
140 (22.0)
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57 (28.9)
0.047
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DQGH[WUDFWHGZLWK%6$7ULWRQ;GLVVROYHG
in PBS for 30 minutes, followed by a further brief wash in 
PBS. Antibodies were diluted in PBS containing 1% BSA 
at optimised concentrations and a 100 µl aliquot added 
to each cover slip for 1 hour. This was followed by 3 × 5 
minutes washes in PBS. Secondary Alexa-Fluor antibodies 
(1:500) and DAPI (1 µg/ml) were diluted in PBS 
containing 1% BSA and a 100 µl aliquot added to each 
cover slip for 1 hour. This was followed by 3 × 5 minutes 
washes. Processed coverslips were mounted onto glass 
slides with 10 µl Shandon immuno-mount (Thermo). 
Microtubule array assays were carried out as previously 
Figure 3: Deactivated CRISPR/Cas9 mediated activation of endogenous CDK18 leads to replication stress response 
defects in breast cancer cells. (A) RT-PCR analysis of endogenous CDK18 mRNA expression levels in two independently derived 
deactivated CRISPR/Cas9 CDK18 activation MDA-MB-231 clones 7A and 8A. CDK18 mRNA levels were normalised to either GAPDH 
or TMBIM6 reference genes as indicated. The data shown represents the mean mRNA expression compared to parental MDA-MB-231 
cells with respective SEMs derived from three independent experiments. (B) Normalised CDK18 protein expression levels in CRISPR/
&DV&'.DFWLYDWLRQ0'$0%FORQHV$DQG$FRPSDUHGWRSDUHQWDO0'$0%FHOOV'DWDVKRZQUHSUHVHQWVWKHTXDQWL¿HG
mean derived from four independent western blot experiments with their respective SEM. (C) Left panel; representative images of 
LPPXQRÀXRUHVFHQFHVWDLQLQJRIȖ+$;LQSDUHQWDO0'$0%FHOOVDQG&'.DFWLYDWLRQFORQHV$DQG$DV LQGLFDWHG5LJKW
SDQHOTXDQWL¿FDWLRQRIȖ+$;QXFOHDUIRFLDQGSDQQXFOHDUȖ+$;VWDLQLQJLQWKHLQGLFDWHGFHOOOLQHV'DWDVKRZQUHSUHVHQWVWKHPHDQV
derived from three independent experiments with their respective SEMs (*p DQG**p FRPSDUHGWRSDUHQWDO0'$0%
cells). (D) Same as in C, but for pRPA2 (Thr21) nuclear foci in untreated and HU treated (3mM, 4hrs) cell lines as indicated. 
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Figure 4: Heightened expression of endogenous CDK18 disrupts replication stress signalling and confers an increased 
sensitivity to replication stress-inducing agents. (A) Representative western blots for the indicated proteins in untreated and HU-
treated parental and CDK18 activation MDA-MB-231 clones. (B) Representative western blots of endogenous RAD9 IPs from parental 
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described [41]. All immunofluorescence images were 
captured on a Nikon Eclipse T200 inverted microscope 
(Melville), equipped with a Hamamatsu Orca ER camera, 
a 200 W metal arc lamp (Prior Scientific, UK) and an 60x 
objective lens and Volocity 3.6.1 software (Improvision). 
Scoring was carried out using exported tiff images for each 
individual condition within an experiment on at least 10 
separate fields of view containing between 200300 cells 
in total. Cells were scored positive for foci if they 
contained >5 discrete foci per nucleus, and the mean 
percentage of positive cells from at least 3 independent 
experiments were then calculated and plotted along with 
their respective standard errors of the means (SEM). 
Quantitative PCR
RNA was extracted from cells using a Qiagen 
RNEasy Plus Kit and quantified on a Nanodrop 
spectrophotometer. Equal quantities of RNA (2 µg) were 
then reverse transcribed using an Applied Biosystems 
High Capacity RNA- cDNA kit as per the manufacturers 
instructions. Resulting cDNAs were appropriately diluted 
into 10 µl Taqman reactions in triplicate using an Applied 
Biosystems Taqman Gene Expression Master Mix and 
Applied Biosystems 7900HT Thermal cycler using the 
manufacturers recommended conditions. Resulting data 
was subsequently analysed using Applied Biosystems SDS 
2.4 software to calculate respective Dct values and relative 
gene expression levels. SYBER Green RT-PCR probes 
used were CDK18; For_TTCTCCCAACAGACAGCGG 
and Rev_GCAGCTGGAACATGAAAATCTTG, GAPDH; 
For_CTGGTAAAGTGGATTGTTGCCAT and Rev_
TGGAATCATATTGGAACATGTAAACC, and TMBIM6 
(TEGT) as previously described [42].
Protein extraction and western blotting
Cell lysates were prepared in RIPA buffer, (50 mM 
Tris-HCL pH 8.0, 150 mM NaCl, 1% (v/v) NP40, 
0.1% (w/v) SDS and 0.5% (w/v) sodium deoxycholate, 
supplemented with protease inhibitors tablets and Phostop 
tablets) for 30 minutes on ice. Resulting lysates were 
clarified at 16,000 × g for 20 minutes. Gel electrophoresis 
was performed using the NuPAGE system (Invitrogen). 
Briefly, samples were resolved on 412% Bis-Tris gels 
in MOPS buffer, transferred to a PVDF membrane. 
Membranes were incubated with antibodies diluted in 
PBS supplemented with 5% milk protein and incubated, 
with agitation, overnight at 4° C. Membranes were washed 
in PBS for 3 × 5 minutes and incubated in appropriate 
secondary antibodies for 1 hour at room temperature. 
The antibodies used for immunoblotting were as follows: 
anti-CDK18 (Santa Cruz Biotechnology: sc-176), anti-
pCDK substrate ([K/H]pSP) MultiMab rabbit Ab mix 
(Cell Signalling), anti-CHK1 (Sigma Aldrich), anti-CHK1 
pS317 (Cell Signaling), anti-RAD9 (Bethyl laboratories: 
A300800A), anti-RPA2 (Calbiochem), anti-RPA2 pT21 
(Abcam), anti-RPA2 pS4/8 (Bethyl Laboratories), anti-
KAP1 (Bethyl Laboratories), anti-KAP1 pS824 (Bethyl 
Laboratories), anti-ATR (Santa Cruz Biotechnology), anti-
Actin (Abcam), HRP-secondary antibodies (DAKO) and 
Alexa-Fluor antibodies (Invitrogen).
Immunoprecipitation
For endogenous RAD9 immunoprecipitation, 2 mg 
of a whole-cell protein extract was added to 30 µl of pre-
washed Protein G fast flow bead slurry (Calbiochem) 
together with 5 µg of mouse monoclonal antibody 
(ab150747 or sc-166457) per mg of whole cell extract, or 
no antibody for the bead only control, and incubated on a 
rotating wheel for 16 hours at 4° C. Beads were pelleted and 
washed several times for 15 mins each wash in 1 ml of TGN 
buffer (150 mM NaCl, 10% glycerol and 1% Tween-20 
supplemented with Benzonase). Pelleted beads were then 
boiled in 2× LDS buffer supplemented with 3 mM DTT 
prior to SDS-PAGE and subsequent western blotting. 
Cell growth and cell cycle analyses
For cell growth assays, Cells were plated at low 
densities in 8 replicates within 96-well plates. After the 
indicated times, MTT reagent was added to the cells at a 
final concentration of 1 mg/ml, and these were incubated 
at 37° C for 3 hrs. The media was removed and 200 µl 
DMSO added to each well to solubilise the formazan 
product. The absorbance of the resulting product was 
assessed by quantifying optical density at 540 nm using a 
spectrophotometric microtitre plate reader. For cell cycle 
analyses, cell cultures were collected with their culture 
media and pelleted. Cell pellets were washed in PBS and 
fixed overnight in 70% Ethanol at 20° C. Fixed samples 
were washed 3 times in PBS before treatment with 5 µg of 
DNAse1 followed by the addition of 300 µl of Propidium 
and CDK18 activation clones using two separate human RAD9 mouse monoclonal antibodies (upper and middle panels as indicated). Equal 
amounts of immunoprecipitates were probed with either RAD9 (rabbit polyclonal) or phospho-CDK substrate (K/HpSP motif; pCDK) 
antibodies as indicated. Inputs demonstrate heightened CDK18 expression in the activation clones and comparable RAD9 expression. 
,J*ZDVXVHGDVDQHJDWLYHFRQWUROIRUQRQVSHFL¿FELQGLQJZKLFKFDQEHVHHQDVDIDLQWEDQGPLJUDWLQJDWDVOLJKWO\KLJKHUPROHFXODU
ZHLJKWWR5$'EODFNDUURZ/HYHOVRIS&'.LQWKH5$',3VZHUHTXDQWL¿HGIURPWKHVHGDWDE\QRUPDOLVLQJWRWKHUHODWLYHDPRXQW
RILPPXQRSUHFLSLWDWHG5$'ZLWKLQHDFKFHOOSRSXODWLRQ7KHORZHUSDQHOVKRZVWKHTXDQWL¿HGDYHUDJHS&'.OHYHOVLQWKHLQGLFDWHG
cell populations with their respective SEMs. (C&ORQRJHQLFVXUYLYDOFXUYHVIRU)8OHIWSDQHODQG0HWKRWUH[DWH07;WUHDWHGULJKW
panel) MDA-MB-231 cell lines as indicated. Data shown represents the mean derived from at least three independent experiments with 
their respective SEMs (*p DQG**p FRPSDUHGWRSDUHQWDO0'$0%FHOOVDWWKHVDPHGUXJGRVH
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Iodide (50 µg/ml) to each sample. FACS acquisition was 
carried out using a FACS-Calibur (Becton-Dickinson) and 
analysed by FlowJo (Tree Star, Inc). 10,000 live cells were 
gated and quantified for each sample.
Clonogenic survival assays
Between 2002000 cells were plated into 6-well 
plates fours hours prior to drug treatments to allow 
cells to attach. When colonies could be observed in the 
control plates (1014 days post-treatment), cells were 
fixed and stained with methylene blue in methanol 
(4 g/L), and colonies consisting of more than 50 cells 
were subsequently scored. Surviving fractions (SF) 
were calculated based on the plating efficiency (fraction 
of colonies formed in untreated plates) for each cell 
population/treatment as; SF = (No. cells counted)/(No. 
cells plated × plating efficiency).
Immunohistochemistry of cell-based sections 
For antibody optimisation experiments, MDA-
MB-231 and MCF-7 cells were transfected with either 
control or CDK18 siRNA for 72 hours as previously 
described [10]. Cells were then washed in PBS, trypsinised, 
pelleted and re-suspended in 1% molten agarose before 
being allowed to cool and set in a 1.5 ml eppendorf tube. 
The resulting cell pellets were then fixed in formalin, 
embedded in paraffin and 3 µm sections were mounted 
onto microscope slides for subsequent staining. Slides were 
imaged using a Leica Leitz DMRB microscope and captured 
ZLWKDQ2VWHRPHDVXUH;3V\VWHPDWDPDJQLILFDWLRQRI[
Commercial tissue microarray staining and 
scoring
Commercial breast cancer tissue microarrays 
(TMAs) were purchased from US Biomax Inc. and 
comprised of 366 readable samples, which included 
334 breast cancers comprising of 292 invasive ductal 
carcinomas, 18 invasive intraductal, 12 invasive lobular, 
4 cystosarcoma phyllodes, 4 medullary, and 4 apocrine 
carcinomas. The remaining samples included 20 normal 
breast tissue, and 18 cancer adjacent tissue samples 
which served as controls. For tissue microarray cores: 
formalin fixed paraffin embedded (FFPE) samples were 
deparaffinised in 2 xylene baths for 510 minutes each. 
Slides were then hydrated through descending grades of 
ethanol (100% to 70%) for 3 minutes each. After washing 
the slides in running water for 5 minutes, the sections 
were then immersed in sodium citrate at pH 6 (Sigma) 
and microwaved for 3 minutes at high temperature and 
7 minutes at low temperature for antigen retrieval. The 
slides were allowed to cool in solution and then washed 
in distilled water for 15 minutes. Sections were then 
soaked in 3% hydrogen peroxide in methanol at 37° C 
for 30 minutes to block endogenous peroxidase activity. 
Following 3 washes in distilled water, slides were then 
incubated for 60 minutes in 10 % normal goat serum 
(Vector Laboratories) and 10% casein in PBS to block 
non-specific binding sites and then probed with the 
relevant primary antibodies prepared in PBS containing 
2% sera and 2% casein overnight at 4° C. Next day, slides 
were rinsed in PBS and then incubated for 60 minutes 
at room temperature in biotinylated goat anti-rabbit 
secondary antibody (Vector Laboratories) prepared at 
1:200 in PBS containing 2% sera and 2% casein. The 
antigen-antibody complexes were detected using the 
Vectastain Elite ABC kit (Vector Laboratories) according 
to manufacturers protocol, followed by staining with 
3,3-diaminobenzidin (DAB) peroxidase substrate kit, 
(Vector Laboratories). Sections were then counterstained 
in Gills haematoxylin and dehydrated in ascending grades 
of ethanol before clearing in xylene and mounting under 
DFRYHUVOLSXVLQJ'3;PRXQWDQW)LVKHU)RUHDFK,+&
staining experiment, FFPE sections of CDK18-proficient 
and deficient cells (see Supplementary Figure 1A and 1B) 
were used as positive and negative controls respectively. 
An additional negative control consisted of omission of the 
primary antibody. Stained TMA slides were scanned using 
an Aperio ScanScope CS digital scanner and resulting 
images analysed by Aperio ImageScope viewing software 
(v11.1). Scoring of CDK18 staining was carried out using 
a 4 scale scoring system of 0; no/negligible staining, +1; 
weak/incomplete staining, 2; moderate staining, and +3; 
strong staining across the tissue section. Scoring of FFPE 
sections in the Nottingham cohort (see below) was carried 
out by two independent people and all sections were 
verified for tumour grade by a consultant pathologist. The 
UHVXOWLQJGDWDZDVGLFKRWRPLVHGXVLQJ;WLOHVVRIWZDUHDV
well at Median/Mean depending on whether the data was 
parametric or non-parametric. 
Analysis of METABRIC datasets
;WLOH YHUVLRQ  ZDV XVHG WR LGHQWLI\ D FXW
off in CDK18 mRNA expression values to divide the 
population in to high/low mRNA expressing subgroups 
prior to analysis. The Chi-square test was used for testing 
association between categorical variables and a multivariate 
Cox model was fitted to the data using as endpoint breast 
cancer specific death. Cumulative survival probabilities 
were estimated using the KaplanMeier method.
Patient study
The study was performed in a consecutive series of 
1650 patients with primary invasive breast carcinomas who 
were diagnosed between 1986 and 1999 and entered into the 
Nottingham Tenovus Primary Breast Carcinoma series [18
21]. All patients were treated uniformly in a single institution 
and have been investigated in a wide range of biomarker 
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studies [1821]. Supplementary Table 2 summarises patient 
demographics. Supplementary treatment data summarizes 
various adjuvant treatments received by patients within 
this cohort. We also evaluated an independent series of 
(5ĮQHJDWLYHLQYDVLYHEUHDVWFDQFHUVGLDJQRVHGDQG
managed at the Nottingham University Hospitals between 
1999 and 2007 [43]. All patients were primarily treated 
with surgery, followed by radiotherapy and anthracycline 
chemotherapy. The characteristics of this cohort are 
summarised in Supplementary Table 3. The Reporting 
Recommendations for Tumour Marker Prognostic Studies 
(REMARK) criteria, recommended by McShane and 
colleagues [44], were followed throughout this study. Breast 
cancer TMAs from these patients were constructed with 2 
replicate 0.6 mm cores from the centre and periphery of the 
tumours. The TMAs were immunohistochemically profiled 
IRU;5&&DQGRWKHUELRORJLFDODQWLERGLHVDVSUHYLRXVO\
described [43]. Immunohistochemical staining for CDK18 
was performed using the Bond Max automated staining 
machine and Leica Bond Refine Detection kit (DS9800) 
according to manufacturer instructions (Leica Microsystems). 
Pre-treatment of TMA sections was performed with citrate 
buffer (pH 6.0) antigen for 20 minutes. TMA sections were 
incubated for 15 minutes at room temperature with 1:100 
anti-CDK18 mouse monoclonal antibody. HER2 expression 
was assessed according to the new ASCO/CAP guidelines 
using IHC and fluorescence in situ hybridisation (FISH). 
To validate the use of TMAs for immunophenotyping, 
full-face sections of 40 cases were stained and protein 
expression levels of the different antibodies were compared. 
The concordance between TMAs and full-face sections 
was deemed excellent (k = 0.8). Positive (normal kidney 
and normal liver tissue) and negative (by omission of the 
primary antibody and IgG-matched serum) controls were 
included in each batch of IHC experiments. Stained TMAs 
were evaluated by three specialist pathologists blinded to 
the clinicopathological characteristics of patients, in two 
different settings. There was excellent intra and inter-observer 
agreements (k !  &RKHQ¶V ț DQG PXOWLUDWHU ț WHVWV
respectively). Whole field inspection of the core was scored 
and intensities of nuclear staining were grouped as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 
3 = strong staining. The percentage of each category was 
estimated (0100%). H-score (range 0300) was calculated 
by multiplying intensity of staining and percentage staining 
as previously described (3033). Low/negative CDK18 
H[SUHVVLRQZDVGHILQHGE\PHDQRI+VFRUHRI1RW
all cores within the TMA were suitable for IHC analysis due 
to missing cores or absence of tumour cells. This work was 
approved by Nottingham Research Ethics Committee.
Statistical analyses
For IHC studies on commercial TMAs and 
Nottingham breast cancer cohort; data analysis was 
performed using SPSS (SPSS, version 17 Chicago, IL). 
Where appropriate, Pearsons Chi-square, Fishers 
exact, Students t and ANOVA one-way tests were used. 
Cumulative survival probabilities were estimated using the 
KaplanMeier method, and differences between survival 
rates were tested for significance using the log-rank test. 
Multivariate analysis for survival was performed using the 
Cox proportional hazard model. The proportional hazards 
assumption was tested using standard log-log plots. Hazard 
ratios (HR) and 95% confidence intervals (95% CI) were 
estimated for each variable. All tests were two-sided with 
a 95% CI and a p value < 0.05 considered significant. For 
multiple comparisons, p values were adjusted according 
to Holm-Bonferroni correction method. For study power 
calculations; sample size and effect size were determined 
using PASS (NCSS, version 11, USA). Cox regression of 
the log hazard ratio on CDK18 covariant (SD = 0.73), based 
on a sample of 1650 observations, achieves 90% power 
at the 0.05 significant level to detect a small regression 
coefficient equal to 0.25 and 0.28 for risk of recurrence and 
death, respectively. The sample size was adjusted since a 
multiple regression of the variable of interest on the other 
covariates in the Cox regression is expected to have an R 
squared of 0.3. The sample size was adjusted for recurrence 
and death event rate of 0.40 and 0.30 respectively. 
Statistically significant differences between quantified 
variables within parental MDA-MB-231 and CDK18 
activation clone cell populations was confirmed using a 
2-tailed t-test, assuming equal variances and are presented 
on figures as *=p **= p 
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SUPPLEMENTARY MATERIALS
Supplementary patient treatment data for 
Nottingham Tenovus BC cohort
Patients received standard surgery (mastectomy or 
wide local excision) with radiotherapy.  Prior to 1989, 
patients did not receive systemic adjuvant treatment 
(AT). After 1989, AT was scheduled based on prognostic 
and predictive factor status, including NPI, oestrogen 
UHFHSWRUĮ(5ĮVWDWXVDQGPHQRSDXVDOVWDWXV3DWLHQWV
with NPI scores of <3.4 (low risk) did not receive AT. 
,Q SUHPHQRSDXVDO SDWLHQWV ZLWK 13, VFRUHV RI 
(high risk), classical Cyclophosphamide, Methotrexate, 
and 5-Flourouracil (CMF) chemotherapy was given; 
SDWLHQWV ZLWK (5Į SRVLWLYH WXPRXUV ZHUH DOVR RIIHUHG
+73RVWPHQRSDXVDOSDWLHQWVZLWK13,VFRUHVRIDQG
(5ĮSRVLWLYLW\ZHUHRIIHUHG+7ZKLOH(5ĮQHJDWLYH
patients received classical CMF chemotherapy. Median 
follow up was 111 months (range 1 to 233 months). 
Survival data, including overall survival, disease-free 
survival (DFS), and development of loco-regional and 
distant metastases (DM), was maintained on a prospective 
EDVLV')6ZDVGH¿QHGDV WKHQXPEHURIPRQWKV IURP
diagnosis to the occurrence of local recurrence, local 
lymph node (LN) relapse or DM relapse.  Breast cancer 
VSHFL¿FVXUYLYDO%&66ZDVGH¿QHGDV WKHQXPEHURI
months from diagnosis to the occurrence of BC related-
GHDWK/RFDOUHFXUUHQFHIUHHVXUYLYDO/56ZDVGH¿QHG
the number of months from diagnosis to the occurrence 
RIORFDOUHFXUUHQFH'0IUHHVXUYLYDOZDVGH¿QHGDVWKH
number of months from diagnosis to the occurrence of 
DM relapse.  Survival was censored if the patient was still 
alive at the time of analysis, lost to follow-up, or died from 
other causes.
Supplementary Figure 1: (A5HSUHVHQWDWLYHLPDJHVRI,+&VWDLQLQJRSWLPLVDWLRQIRU&'.LQ0&)FHOOVWUDQVIHFWHGZLWKFRQWURO
QRQWDUJHWLQJRUSUHYLRXVO\YDOLGDWHG&'.VL51$>@DVLQGLFDWHG7KHLPDJHVLQWKHOHIWDQGULJKWSDQHOVUHSUHVHQWWZRLQGHSHQGHQW
experiments. (B$VLQ$EXWLQ0&)OHIWSDQHODQG0'$0%FHOOVULJKWSDQHOIURPDQDGGLWLRQDOH[SHULPHQWDOUHSHDWC) 
5HSUHVHQWDWLYHLPDJHVRI&'.,+&VWDLQLQJDWEDVHGRQWKHRSWLPLVDWLRQGDWDDERYHLQFRPPHUFLDOEUHDVWFDQFHU70$VD) 
6FRULQJRI&'.,+&VWDLQLQJLQFRPPHUFLDOEUHDVWFDQFHU70$V/HIWSDQHOUHSUHVHQWDWLYHLPDJHVWRKLJKOLJKWWKHVFRULQJV\VWHPXVHG
5LJKWSDQHOTXDQWL¿FDWLRQRI&'.VFRULQJDFURVVWKHYDULRXVQRUPDODQGWXPRXUVDPSOHVZLWKLQWKH70$V 
Supplementary Figure 2: (AC .DSODQ0HLHU VXUYLYDO FXUYHV IRU &'. SURWHLQ H[SUHVVLRQ DERYH RU EHORZ PHGLDQ SORWWHG
DJDLQVWEUHDVWFDQFHUVSHFL¿FVXUYLYDOIRU(5WXPRXUVZLWKLQWKH1RWWLQJKDP7HQRYXVEUHDVWFDQFHUFRKRUWVWUDWL¿HGXVLQJWKHLQGLFDWHG
clinicopathological parameters. (D) 4XDQWL¿FDWLRQRIFHOOF\FOHSKDVHVLQSDUHQWDO0'$0%FHOOVDQG&'.DFWLYDWLRQFORQHVDV
LQGLFDWHG'DWDVKRZQUHSUHVHQWVWKHPHDQGHULYHGIURPDWOHDVWWZRLQGHSHQGHQWH[SHULPHQWVZLWKWKHLUUHVSHFWLYH6(0VE) Growth of 
&5,635&'.NQRFNRXWDQGDFWLYDWLRQFORQHVFRPSDUHGZLWKSDUHQWDO0'$0%FHOOVRYHUGD\RUGD\SHULRGDVLQGLFDWHG
'DWDVKRZQUHSUHVHQWVWKHPHDQGHULYHGIURPDWOHDVW¿YHLQGHSHQGHQWH[SHULPHQWVZLWKWKHLUUHVSHFWLYH6(0VF&'.P51$DQG
protein expression levels within individual tumours in the Nottingham Tenovus breast cancer cohort showing a lack of correlation between 
the two in 86 individual tumours. 
Supplementary Table 1: Clinicopathological characteristics of the Nottingham Tenovus breast cancer cohort
Variable n* Cases (%)
Menopausal status 
Pre-menopausal 612 
postmenopausal  
Tumour Grade (NGS) 
G1  (18.5)
G2 531 (32.2)
G3 813 (49.3)
Lymph node stage 
Negative  
Positive (13 nodes) 486 (29.5) 
Positive (>3 nodes)  (6.5)
Tumour size (cm) 
7DE  
7F!± 868 
7!±  
T3 (>5) 16 
Tumour type 
IDC-NST 941 
Tubular 349 (21)
ILC  
Medullary (typical/atypical) 41 (2.5) 
Others 159 (9.5)
NPI subgroups 
([FHOOHQW3*± Low risk  (12.5)
*RRG3*± 331 
Moderate I PG (3.42 to 4.4) High risk 488 (29.6)
Moderate II PG (4.42 to 5.4) 395 (23.9)
Poor PG (5.42 to 6.4)  
Very poor PG (6.56.8) 59 (3.6)
Survival at 20 years 
Alive and well  
Dead from disease 468 (28.4) 
Dead from other causes  
Adjuvant systemic therapy (AT)
No AT 665 
Hormone therapy (HT) 642 
Chemotherapy  
+RUPRQHFKHPRWKHUDS\ 46 
Supplementary Table 2: Clinicopathological characteristics of validation set of ER negative breast cancer patient 
samples
Variable n* Cases (%)
Menopausal status 252
Pre-menopausal 122 (48.5)
postmenopausal  (51.5)
Tumour Grade (NGS) 252
G1 1 
G2  
G3 224 (89.1)
Lymph node stage 252
Negative 121 (48) 
Positive (13 nodes) 86 (34)
Positive (>3 nodes) 45 (18)
Tumour size (cm) 252
7DE 28 (11)
7F!±  (42)
7!±  (41)
T3 (>5) 15 (6)
Tumour type 252
IDC-NST 224 
Tubular 5 
ILC 8 
Medullary (typical/atypical) 5 
Others  
NPI subgroups 252
([FHOOHQW3*± Low risk  
*RRG3*±  
Moderate I PG (3.42 to 4.4) High risk 111 
Moderate II PG (4.42 to 5.4) 81 
Poor PG (5.42 to 6.4) 38 
Very poor PG (6.56.8) 22 
Survival at 5 years 252
Alive and well  
Dead from disease  
Dead from other causes 3 
Supplementary Table 3: Clinicopathological characteristics of validation set of ER negative BC patient samples
Variable n* Cases (%)
Menopausal status 252
Pre-menopausal 122 (48.5)
postmenopausal  (51.5)
Tumour Grade (NGS) 252
G1 1 
G2   
G3 224 (89.1)
Lymph node stage 252
Negative 121  (48)
Positive (13 nodes) 86 (34) 
Positive (>3 nodes) 45 (18)
Tumour size (cm) 252
7DE 28 (11)
7F!±  (42)
7!±     (41)
T3 (>5) 15 (6)
Tumour type 252
IDC-NST 224 
Tubular 5 
ILC 8 
Medullary (typical/atypical) 5 
Others  
NPI subgroups 252
([FHOOHQW3*± Low risk  
*RRG3*±  
Moderate I PG (3.42 to 4.4) High risk 111 
Moderate II PG (4.42 to 5.4) 81 
Poor PG (5.42 to 6.4) 38 
Very poor PG (6.56.8) 22 
Survival at 5 years 252
Alive and well   
Dead from disease  
Dead from other causes 3 
